RFA
ABUS icon

Reilly Financial Advisors’s Arbutus Biopharma ABUS Stock Holding History

Reilly Financial Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$0 Buy
+75
New +$291 ﹤0.01% 1116
2019
Q1 		– Sell
-100
Closed – – 956
2018
Q4 		$0 Buy
+100
New +$493 ﹤0.01% 930

Other funds holding ABUS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return

Reilly Financial Advisors's ABUS Position: Q4 2021 in Review

Reilly Financial Advisors opened a new position in Arbutus Biopharma (ABUS) in Q4 2021: 75 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1116 among its holdings. This is a return to the name: Reilly Financial Advisors previously reported a position in ABUS as recently as Q4 2018.

Reilly Financial Advisors first reported a position in ABUS in Q4 2018 and has held it in 2 quarters since. 123 funds tracked by Wall St. Rank hold ABUS as of Q4 2021.

  • Reilly Financial Advisors held 75 shares of Arbutus Biopharma worth $0 as of Q4 2021.
  • Arbutus Biopharma was a new Reilly Financial Advisors position in Q4 2021.
  • Arbutus Biopharma made up ﹤0.01% of Reilly Financial Advisors's portfolio in Q4 2021, its #1116 holding.
  • Reilly Financial Advisors first reported a position in Arbutus Biopharma in Q4 2018 and has held it in 2 quarters since.
  • 123 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2021.

Based on Reilly Financial Advisors's 13F filing for Q4 2021, filed 25 Jan 2022.